Conv. Plasma
Nigella Sativa

All ivermectin studies
Meta analysis
study COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Ivermectin: an award-winning drug with expected antiviral activity against COVID-19

Formiga et al., J. Control Release, doi:10.1016/j.jconrel.2020.10.009
Jan 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
*, now known with p < 0.00000000001 from 102 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
Review hypothesizing that micro- and nanotechnology-based formulations of ivermectin for the pulmonary delivery of ivermectin may be beneficial for use with COVID-19.
Formiga et al., 10 Jan 2021, peer-reviewed, 6 authors.
This PaperIvermectinAll
Ivermectin: an award-winning drug with expected antiviral activity against COVID-19
Fabio Rocha Formiga, Roger Leblanc, Juliana De Souza Rebouças, Leonardo Paiva Farias, Ronaldo Nascimento De Oliveira, Lindomar Pena
Journal of Controlled Release, doi:10.1016/j.jconrel.2020.10.009
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre -including this research content -immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Declaration of Competing Interest The authors deny the existence of any conflicts of interest.
Ali, Afzal, Verma, Bhattacharya, Ahmad et al., Therapeutic efficacy of poly (lactic-co-glycolic acid) nanoparticles encapsulated ivermectin (nano-ivermectin) against brugian filariasis in experimental rodent model, Parasitol. Res, doi:10.1007/s00436-013-3696-5
Ali, Afzal, Verma, Misra-Bhattacharya, Ahmad et al., Improved antifilarial activity of ivermectin in chitosan-alginate nanoparticles against human lymphatic filarial parasite, Brugia malayi, Parasitol. Res, doi:10.1007/s00436-013-3466-4
Barrows, Campos, Powell, Prasanth, Schott-Lerner et al., A screen of FDA-approved drugs for inhibitors of Zika virus infection, Cell Host Microbe, doi:10.1016/j.chom.2016.07.004
Callaway, Cyranoski, Anti-parasite drugs sweep Nobel prize in medicine 2015, Nature, doi:10.1038/nature.2015.18507
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antivir. Res, doi:10.1016/j.antiviral.2020.104787
Camargo, Sapin, Daloz, Maincent, Ivermectin-loaded microparticles for parenteral sustained release: in vitro characterization and effect of some formulation variables, J. Microencapsul, doi:10.3109/02652048.2010.501397
Chaccour, Ruiz-Castillo, Richardson, Moncunill, Casellas et al., The SARS-CoV-2 Ivermectin Navarra-ISGlobal trial (SAINT) to evaluate the potential of ivermectin to reduce COVID-19 transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: a structured summary of a study protocol for a randomized control pilot trial, Trials, doi:10.1186/s13063-020-04421-z
Chan, Nano research for COVID-19, ACS Nano, doi:10.1021/acsnano.0c02540
Cojocaru, Botezat, Gardikiotis, Uritu, Dodi et al., Nanomaterials designed for antiviral drug delivery transport across biological barriers, Pharmaceutics, doi:10.3390/pharmaceutics12020171
Croci, Bottaro, Chan, Watanabe, Pezzullo et al., Liposomal systems as nanocarriers for the antiviral agent Ivermectin, Int. J. Biomater, doi:10.1155/2016/8043983
Ebbelaar, Venema, Van Dijk, Topical ivermectin in the treatment of Papulopustular rosacea: a systematic review of evidence and clinical guideline recommendations, Dermatol. Ther. (Heidelb), doi:10.1007/s13555-018-0249-y
Ghadiri, Young, Traini, Strategies to enhance drug absorption via nasal and pulmonary routes, Pharmaceutics, doi:10.3390/pharmaceutics11030113
Ho, Nichols, Edgar, Murgia, Loretz et al., Challenges and strategies in drug delivery systems for treatment of pulmonary infections, Eur. J. Pharm. Biopharm, doi:10.1016/j.ejpb.2019.09.002
Ketkar, Yang, Wormser, Wang, Lack of efficacy of ivermectin for prevention of a lethal Zika virus infection in a murine system, Diagn. Microbiol. Infect. Dis, doi:10.1016/j.diagmicrobio.2019.03.012
Liu, Guan, Qin, Zhang, Mao, Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery, Drug Discov. Today, doi:10.1016/j.drudis.2019.09.023
Lv, Liu, Wang, Dang, Qiu et al., Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo, Antivir. Res, doi:10.1016/j.antiviral.2018.09.010
Newman, Drug delivery to the lungs: challenges and opportunities, Ther. Deliv, doi:10.4155/tde-2017-0037
Ono, Tatsuo, Hidaka, Aoki, Minagawa et al., Measles viruses on throat swabs from measles patients use signaling lymphocytic activation molecule (CDw150) but not CD46 as a cellular receptor, J. Virol, doi:10.1128/JVI.75.9.4399-4401.2001
Onoue, Yamada, Chan, Nanodrugs: pharmacokinetics and safety, Int. J. Nanomedicine, doi:10.2147/IJN.S38378
Paranjpe, Müller-Goymann, Nanoparticle-mediated pulmonary drug delivery: a review, Int. J. Mol. Sci, doi:10.3390/ijms15045852
Pedersen, Ho, SARS-CoV-2: a storm is raging, J. Clin. Invest, doi:10.1172/JCI137647
Rizzo, Ivermectin, antiviral properties and COVID-19: a possible new mechanism of action, Naunyn Schmiedeberg's, Arch. Pharmacol, doi:10.1007/s00210-020-01902-5
Sandler, Firpo, Omoba, Vu, Menachery et al., Novel ionophores active against La Crosse virus identified through rapid antiviral screening, Antimicrob. Agents Chemother, doi:10.1128/AAC.00086-20
Schmith, Zhou, Lohmer, The approved dose of ivermectin alone is not the Ideal dose for the treatment of COVID-19, Clin. Pharmacol. Ther, doi:10.1002/cpt.1889
Surnar, Kamran, Shah, Basu, Kolishetti et al., Orally administrable therapeutic synthetic nanoparticle for Zika virus, ACS Nano, doi:10.1021/acsnano.9b02807
Takano, Sugano, Higashida, Hayashi, Machida et al., Oral absorption of poorly water-soluble drugs: computer simulation of fraction absorbed in humans from a miniscale dissolution test, Pharm. Res, doi:10.1007/s11095-006-0162-4
Ullio-Gamboa, Palma, Benoit, Allemandi, Picollo et al., Ivermectin lipid-based nanocarriers as novel formulations against head lice, Parasitol. Res, doi:10.1007/s00436-017-5510-2
Varghese, Kaukinen, Glasker, Bespalov, Hanski et al., Discovery of berberine, abamectin and ivermectin as antivirals against chikungunya and other alphaviruses, Antivir. Res, doi:10.1016/j.antiviral.2015.12.012
Wang, Lv, Ji, Wang, Qiu et al., Ivermectin treatment inhibits the replication of porcine circovirus 2 (PCV2) in vitro and mitigates the impact of viral infection in piglets, Virus Res, doi:10.1016/j.virusres.2019.01.010
Wölfel, Corman, Guggemos, Virological assessment of hospitalized patients with COVID-2019, Nature, doi:10.1038/s41586-020-2196-x
Xu, Han, Liu, Pang, Zheng et al., Antivirus effectiveness of ivermectin on dengue virus type 2 in Aedes albopictus, PLoS Negl. Trop. Dis, doi:10.1371/journal.pntd.0006934
Yan, Ci, Chen, Chen, Li et al., Anti-inflammatory effects of ivermectin in mouse model of allergic asthma, Inflamm. Res, doi:10.1007/s00011-011-0307-8
Yang, Atkinson, Wang, Lee, Bogoyevitch et al., The broad spectrum antiviral ivermectin targets the host nuclear transport importin alpha/beta1 heterodimer, Antivir. Res, doi:10.1016/j.antiviral.2020.104760
Zhang, Song, Ci, An, Ju et al., Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflamm. Res, doi:10.1007/s00011-008-8007-8
Zhang, Zhou, Wei, Yue, Wang et al., Histopathologic changes and SARS-CoV-2 imunostaining in the lung of a patient with COVID-19, Ann. Intern. Med, doi:10.7326/M20-0533
Zheng, Fan, Yu, Feng, Lou et al., Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang Province, China, BMJ, doi:10.1136/bmj.m1443
Zhou, Leung, Tang, Parumasivam, Loh et al., Inhaled formulations and pulmonary drug delivery systems for respiratory infections, Adv. Drug Deliv. Rev, doi:10.1016/j.addr.2014.10.022
Zhou, Yang, Wang, A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature, doi:10.1038/s41586-020-2012-7
Zou, Ruan, Huang, Liang, Huang et al., SARS-CoV-2 viral load in upper respiratory specimens of infected patients, N. Engl. J. Med, doi:10.1056/NEJMc2001737
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop